Evidence map›Paper›PMID 35631640›Full record

ReviewPharmaceutics2022

Plasma-Enabled Smart Nanoexosome Platform as Emerging Immunopathogenesis for Clinical Viral Infection.

Seyyed Mojtaba Mousavi, Seyyed Alireza Hashemi, Ahmad Gholami, Masoomeh Yari Kalashgrani, Neralla Vijayakameswara Rao, Navid Omidifar, Wesley Wei-Wen Hsiao, Chin Wei Lai, Wei-Hung Chiang

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Seyyed Mojtaba MousaviDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.
Seyyed Alireza HashemiNanomaterials and Polymer Nanocomposites Laboratory, School of Engineering, University of British Columbia, Kelowna, BC V1V 1V7, Canada.
Ahmad GholamiBiotechnology Research Center, Shiraz University of Medical Science, Shiraz 71468-64685, Iran.ORCID 0000-0003-1851-159X
Masoomeh Yari KalashgraniBiotechnology Research Center, Shiraz University of Medical Science, Shiraz 71468-64685, Iran.ORCID 0000-0001-8836-2388
Neralla Vijayakameswara RaoDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0001-8534-7158
Navid OmidifarDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Wesley Wei-Wen HsiaoDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0002-1346-327X
Chin Wei LaiNanotechnology and Catalysis Research Centre (NANOCAT), Institute for Advanced Studies (IAS), Universiti Malaya (UM), Level 3, Block A, Kuala Lumpur 50603, Malaysia.ORCID 0000-0002-7549-5015
Wei-Hung ChiangDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0002-6350-6696
National Taiwan University of Science and Technology · TWShiraz University · IRShiraz University of Medical Sciences · IRUniversity of British Columbia · CAUniversity of Malaya · MY

Funding

FRGS/1/2020/TK0/UM/02/8 FP023-2020University of Malaya Global Collaborative Pro-gramme - SATU Joint Research Scheme (No. ST004-2021)
6 · The paper itself

Abstract

Smart nanoexosomes are nanosized structures enclosed in lipid bilayers that are structurally similar to the viruses released by a variety of cells, including the cells lining the respiratory system. Of particular importance, the interaction between smart nanoexosomes and viruses can be used to develop antiviral drugs and vaccines. It is possible that nanoexosomes will be utilized and antibodies will be acquired more successfully for the transmission of an immune response if reconvalescent plasma (CP) is used instead of reconvalescent plasma exosomes (CPExo) in this concept. Convalescent plasma contains billions of smart nanoexosomes capable of transporting a variety of molecules, including proteins, lipids, RNA and DNA among other viral infections. Smart nanoexosomes are released from virus-infected cells and play an important role in mediating communication between infected and uninfected cells. Infections use the formation, production and release of smart nanoexosomes to enhance the infection, transmission and intercellular diffusion of viruses. Cell-free smart nanoexosomes produced by mesenchymal stem cells (MSCs) could also be used as cell-free therapies in certain cases. Smart nanoexosomes produced by mesenchymal stem cells can also promote mitochondrial function and heal lung injury. They can reduce cytokine storms and restore the suppression of host antiviral defenses weakened by viral infections. This study examines the benefits of smart nanoexosomes and their roles in viral transmission, infection, treatment, drug delivery and clinical applications. We also explore some potential future applications for smart nanoexosomes in the treatment of viral infections.

Indexed as

convalescent plasmadrug deliverysmart nanoexosomesviral infections

Identifiers

PMID35631640
PMCPMC9145689
OpenAlexW4280510673

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.